05:32 PM EDT, 03/17/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said late Monday it has amended a global licensing deal for JNJ-1900 with Johnson & Johnson's ( JNJ ) Janssen Pharmaceutica, extending its cash visibility.

The amendment removed Nanobiotix's ( NBTX ) funding obligation for the NANORAY-312 trial, while releasing Johnson & Johnson ( JNJ ) from some potential milestone payments, Nanobiotix ( NBTX ) said.

"We are pleased by what we view as a favorable cost of capital resulting from this amendment," said Chief Financial and Business Officer Bart Van Rhijn.

Under the amended deal, Johnson & Johnson ( JNJ ) will cover NANORAY-312 costs through completion, Nanobiotix ( NBTX ) said, adding the value of the licensing deal has decreased to about $2.6 billion from about $2.7 billion.

The amended deal would extend its cash visibility to mid-2026, the firm said. It is also exploring financing options, preferably non-dilutive, to further extend its runway into 2027.